*together with TheoTrade
Good day, 360!
Urgent webinar reminder – learn how Blake is BEATING the S&P 500 three times over… today at 1pm EST → lock in your seat here!
And while you’re at it, check out Jason Bond’s Ultimate Options Trading Blueprint For Small Accounts. He’s on a HUGE winning streak. Trading is hard, but with Jason at your side, you can come into the arena prepared!
FOCUS LIST🔎
BLMZ – Up over 60% in the pre-market after being selected as the primary animation production contractor for an upcoming animation project
TVGN – Up over 40% in pre after highlighting promising trial data as CEO leads patient advocacy at Capitol Hill, pledging to leverage multi-billion dollar company assets to combat long COVID and spearhead a new wave of medical innovation
TPST – Up over 40% in pre after announcing agreement with Roche to support advancement of Amezalpat combination therapy into first-line Hepatocellular Carcinoma pivotal trial
*together with TheoTrade
Buy and Hold as you know by now is DEAD😵.
But that doesn’t mean your portfolio is…
Tripling the S&P 500 isn’t just a dream, it’s happening.
HOTLIST🔥
BLMZ – Up over 60% in the pre-market after being selected as the primary animation production contractor for an upcoming animation project
BloomZ Inc. (BLMZ) is a Japanese anime production, audio production, and voice actor management company.
In the after-hours yesterday, the company announced that it was selected by the animation production committee of “Kakushite! Makina-san!,” an animation project scheduled to begin airing in 2025 as the primary animation production contractor.
In addition to becoming the primary animation production contractor for the Animation Production Committee, BloomZ has acquired the following rights:
Neighboring rights and ownership of the master recording of the opening music;
Overseas rights (which include theatrical distribution rights, television broadcasting rights, videogame rights, and all other rights to use the animation overseas); and
Commercialization rights and digital content rights (including the right to produce digital games).
The stock traded up over 60% in the pre-market in reaction to the news.
The $1.09 area acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $1.20 and then the pre-market high at $1.33. Beyond that, $1.70 and $2 come into play.
Below $1.09, targets to the downside are $1, $0.85 and then a gap fill at $0.7152.
TVGN – Up over 40% in pre after highlighting promising trial data as CEO leads patient advocacy at Capitol Hill, pledging to leverage multi-billion dollar company assets to combat long COVID and spearhead a new wave of medical innovation
Tevogen Bio (TVGN) is a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers.
In the after-hours yesterday the company reissued its previously announced topline results from its Proof-of-Concept (POC) clinical trial designed to evaluate the safety and feasibility of TVGN 489, the company’s first clinical product utilizing the internally developed ExacTcell™ technology, for the treatment of acute high-risk SARS-CoV-2 patients.
Highlights Include:
The primary study endpoints were related to safety. No dose-limiting toxicities or significant adverse events related to TVGN 489, including Cytokine Release Syndrome, were observed in any patient at any dose level.
Endpoints measuring the reduction of viral load and the presence of cellular and humoral anti-COVID-19 responses after treatment were met.
Fifty percent (50%) of treatment arm patients were immunocompromised versus six percent (6%) of observational arm patients.
Treatment arm patients were infected by a variety of SARS-CoV-2 variants ranging from Delta through Omicron BA.5.2.
Observational arm patients were treated with standard of care including monoclonal antibodies.
Key observational findings: All treatment arm patients returned to their baseline level of health within 14 days of treatment. No evidence of COVID reinfection or Long COVID was observed in any treated patient at the time of the six (6) month follow up.
The stock traded up over 40% in the pre-market in reaction to the results.
The $0.35 area acted as support in the after-hours and pre-market and is an important level to watch.
Above it, targets to the upside are $0.40, $0.45 and then the pre-market high at $0.4870. Beyond that, $0.51, $0.57, $0.64 and $0.73 come into play.
Below $0.35, targets to the downside are $0.28 and then a gap fill at $0.2593.
“Money Isn’t Evil.”
Life’s BEST Investments Come At A Price.
Trading With Jason As He COMPOUNDS $2000!
+1,618%*
1-443-269-8824 / [email protected] W/ Questions.
*Results not typical. Performance not promised. Don’t expect to replicate.
TPST – Up over 40% in pre after announcing agreement with Roche to support advancement of Amezalpat combination therapy into first-line Hepatocellular Carcinoma pivotal trial
Tempest Therapeutics Inc. (TPST) is a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer.
In the pre-market the company announcedan agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq®) and bevacizumab, the current standard of care for unresectable or metastatic hepatocellular carcinoma (HCC), into a pivotal Phase 3 trial for the first-line treatment of unresectable or metastatic hepatocellular carcinoma, a form of liver cancer with high unmet need.
Under the agreement, Roche will supply atezolizumab globally and Tempest will sponsor and lead the pivotal study.
According to Finviz, based on yesterday’s close TPST had a market cap of just $34.03 million. Roce has a market cap of over $200 billion based on yesterday’s close according to Yahoo Finance.
TSPT stock traded up over 40% in the pre-market in reaction to the partnership.
The $1.74 area found buyers in the pre-market before breaking through resistance and will be an important level to watch.
Above it, targets to the upside are $1.88, $1.95 and then the pre-market high at $2.03. Beyond that, $2.20 and $2.70 come into play.
Below $1.74, targets to the downside are $1.60, $1.50, $1.40 and then a gap fill at $1.35.
MARKET NEWS 📰
P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas!
Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull
DISCLAIMER: To more fully understand any Ragingbull.com, LLC (“RagingBull”) subscription, website, application or other service (“Services”), please review our full disclaimer located at https://ragingbull.com/disclaimer
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers’ trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers.
RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.
*Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
